The document describes a novel platform called MultiOmyx that enables simultaneous imaging of protein and nucleic acid biomarkers at a subcellular level in tissue samples. It allows for quantification of biomarkers in individual cells while preserving spatial architecture. Analysis of a colon cancer cohort revealed extensive immune cell heterogeneity between patients and unexpected patterns of signal transduction pathway activation at single cell levels. This highlights the unique capability of MultiOmyx to provide novel insights into biological mechanisms through multiomic, hyper-plexed tissue analysis.